Business
personalised medicine, and BGI, (Beijing,China) the world’s largest genome organisation, have announced the successful completion of a project dedicated to expanding Exonhit’s Genome-Wide SpliceArrayTM animal model species.
to an additional strategic preclinical
“Combining BGI’s next-generation sequencing ability with the profiling efficiency of Exonhit unique SpliceArray™ platform to discover new transcript content will enable a better understanding of the biology contributing to the onset and progression of disease. This new powerful combination will facilitate the rapid discovery, development and
Opportunities Europe and Middle East
By Heather Hobbs
With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Europe and the Middle East. This section of Lab Asia will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Exonhit and BGI Complete Sequencing Project Exonhit (Paris, France), a biotech company focused on
commercialisation of the most relevant therapeutics, biomarkers and molecular diagnostics. We look forward to working with BGI as a preferred partner on future discovery projects,” commented Matthew Pando, PhD., Executive Vice President, Therapeutics at Exonhit.
“There is a high need for biomarker discovery as Pharma and Biotech players search for prognostic and predictive biomarkers in animal models, for designing clinical trials and developing companion diagnostics,” said Zifei Yang, Director of Pharma Business Development at BGI. “BGI Europe is pleased to partner with Exonhit to leverage BGI’s next-generation sequencing technology with Exonhit’s SpliceArray™ platform.”
TO FIND OUT MORE CIRCLE NO. 454 MS Instrument Receives R&D 100 Award
Spectro Analytical Instruments was named among the winners of the 49th annual R&D 100 Awards for the development of array detection technology for mass spectrometers along with the technology’s co-developers—Pacific Northwest National Laboratory, the University of Arizona, Indiana University and iMAGERLABS.
Spectro was cited for its role in the commercialisation of the breakthrough technology with the introduction of the Spectro MS inductively coupled plasma (ICP) mass spectrometer in March 2010. The instrument also was awarded a 2010 Silver Pittcon Editors’ Award for Best New Product at the 2010 Pittsburgh Conference and a 2011 Annual Conference of China Scientific Instruments (ACCSI) Award as “one of the best new instruments 2010”.
“We are extremely pleased to be selected along with our co- developers for this prestigious award,” comments Manfred Bergsch, Managing Director, Spectro Analytical Instruments GmbH, Kleve, Germany. “It confirms our belief that Spectro MS represents a breakthrough that changes ICP mass spectrometry forever.
“With its ability to simultaneously measure the complete elemental spectrum, we believe the Spectro MS will
revolutionise the mass spectrometry market the same way the introduction of simultaneous optical emission spectrometers did several years ago,” he adds.
Established by the editors of R&D magazine in 1963, the R&D 100 Award is presented annually to the 100 most significant new developments in research and development as determined by an independent panel of judges and the editors of R&D.
TO FIND OUT MORE CIRCLE NO. 456 Lab M Adds Spanish Partner to Network
Microbiological culture media specialist Lab M (Bury, UK) has appointed Akralab S.L., a supplier to the Food and Agricultural sectors in Spain, as a distribution partner.
Tono Jordá Mora, director commercial marketing at Akralab, based in Alicante, commented “Lab M’s products fit very well with our existing laboratory portfolio; - our track record as a supplier to the food industry and to a wide range of blue-chip companies in
Spain means we are well placed to supply and support the Lab M range. I look forward to a very productive time ahead.”
Phil Large, Sales & Marketing Manager for Lab M, said: “It’s a pleasure to be working with Akralab. Our joint activities are already promoting and growing the use of Lab M media in the region, and the partnership will provide users of our products with local support to complement the centralised services that we offer.”
TO FIND OUT MORE CIRCLE NO. 457
Edwards, a world leader in vacuum technology, has officially opened its first volume vacuum pump manufacturing facility in mainland Europe, after investing approximately £47 million in the site at Lutín, Czech Republic. This has now been designated the new global centre for manufacturing the company’s range of vacuum pumps used across a variety of applications. This brings Edwards’ total number of manufacturing sites around the world to seven, including sites in the UK, Korea and Japan. In addition, the company has 12 service centres situated around the world, including one in Brno (Czech Republic) and one in Munich (Germany).
Does your company sell or wish to sell laboratory products and services to the economies of Europe and the Middle East? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate. Contact us today for more information Email:
info@intlabmate.com
“We are delighted to open our new world class facility in Lutín, which will help sustain our leadership of the global vacuum market,” says Matthew Taylor, Chief Executive Officer at Edwards. “Our significant investment in this new site enables us to manufacture closer to customers in central Europe, which improves our response times. It also allows us to raise the bar in sustainable manufacturing, product quality and performance.” Through investing in the site, Edwards has created 600 jobs in the region and there are many opportunities for local graduates to become part of the global vacuum technology company.
“We are excited to open this new site in Lutín and to become part of the local community,” says Wolfgang Binder, European General Manager at Edwards.
TO FIND OUT MORE CIRCLE NO. 458
NIMGenetics Becomes CSP for Agilent Genomics System
NIMGenetics S.L. of Madrid has achieved Certified Service Provider (CSP) status for genomic research using Agilent SurePrint comparative genomic hybridisation (CGH) and CGH/SNP microarrays.
We are very proud to become the first Agilent CSP in Spain," said Dr. Juan Cruz Cigudosa, NIMGenetics Chief Scientific Officer. "We offer personalised customer service for research professionals that helps them with the design and selection of the most appropriate platform, up to a complete bioinformatics analysis, working with arrayCGH, gene expression arrays and microRNA platforms. NIMGenetics provides services in Spain and worldwide, offering the best products to improve characterisation reliability.
"We're very pleased to welcome this esteemed organisation to our growing team of CSPs," said Robert Schueren, Agilent Vice President and General Manager, Genomics. "NIMGenetics has a history of innovation and quality in investigating the effects of alterations in DNA copy numbers, and it's gratifying to see Agilent CGH tools performing a substantial role in this work."
"We have been collaborating for years with NIMGenetics and their associated academic partners," added Pascal Le Floch-Riché, Agilent Southern Europe genomics sales manager. "Their advanced team specialises in the development of genetic research and, supported by our leading array technology, has been accredited by the Spanish Association of Human Genetics."
TO FIND OUT MORE CIRCLE NO. 455
Edwards Opens Volume Manufacturing Site in Mainland Europe
To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
